Literature DB >> 23633489

Critical role of STAT3 in IL-6-mediated drug resistance in human neuroblastoma.

Tasnim Ara1, Rie Nakata, Michael A Sheard, Hiroyuki Shimada, Ralf Buettner, Susan G Groshen, Lingyun Ji, Hua Yu, Richard Jove, Robert C Seeger, Yves A DeClerck.   

Abstract

Drug resistance is a major cause of treatment failure in cancer. Here, we have evaluated the role of STAT3 in environment-mediated drug resistance (EMDR) in human neuroblastoma. We determined that STAT3 was not constitutively active in most neuroblastoma cell lines but was rapidly activated upon treatment with interleukin (IL)-6 alone and in combination with the soluble IL-6 receptor (sIL-6R). Treatment of neuroblastoma cells with IL-6 protected them from drug-induced apoptosis in a STAT3-dependent manner because the protective effect of IL-6 was abrogated in the presence of a STAT3 inhibitor and upon STAT3 knockdown. STAT3 was necessary for the upregulation of several survival factors such as survivin (BIRC5) and Bcl-xL (BCL2L1) when cells were exposed to IL-6. Importantly, IL-6-mediated STAT3 activation was enhanced by sIL-6R produced by human monocytes, pointing to an important function of monocytes in promoting IL-6-mediated EMDR. Our data also point to the presence of reciprocal activation of STAT3 between tumor cells and bone marrow stromal cells including not only monocytes but also regulatory T cells (Treg) and nonmyeloid stromal cells. Thus, the data identify an IL-6/sIL-6R/STAT3 interactive pathway between neuroblastoma cells and their microenvironment that contributes to drug resistance. ©2013 AACR.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23633489      PMCID: PMC3740971          DOI: 10.1158/0008-5472.CAN-12-2353

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  50 in total

1.  Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells.

Authors:  Tanya Gritsko; Ann Williams; James Turkson; Satoshi Kaneko; Tammy Bowman; Mei Huang; Sangkil Nam; Ibrahim Eweis; Nils Diaz; Daniel Sullivan; Sean Yoder; Steve Enkemann; Steven Eschrich; Ji-Hyun Lee; Craig A Beam; Jin Cheng; Susan Minton; Carlos A Muro-Cacho; Richard Jove
Journal:  Clin Cancer Res       Date:  2006-01-01       Impact factor: 12.531

Review 2.  Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling.

Authors:  Simon A Jones; Jürgen Scheller; Stefan Rose-John
Journal:  J Clin Invest       Date:  2011-09-01       Impact factor: 14.808

3.  A phase I study of zoledronic acid and low-dose cyclophosphamide in recurrent/refractory neuroblastoma: a new approaches to neuroblastoma therapy (NANT) study.

Authors:  Heidi V Russell; Susan G Groshen; Tasnim Ara; Yves A DeClerck; Randy Hawkins; Hollie A Jackson; Heike E Daldrup-Link; Araz Marachelian; Andrej Skerjanec; Julie R Park; Howard Katzenstein; Katherine K Matthay; Susan M Blaney; Judith G Villablanca
Journal:  Pediatr Blood Cancer       Date:  2010-11-12       Impact factor: 3.167

4.  Survivin mRNA levels are associated with biology of disease and patient survival in neuroblastoma: a report from the children's oncology group.

Authors:  Michal A Miller; Kensuke Ohashi; Xiaoyan Zhu; Patrick McGrady; Wendy B London; Michael Hogarty; Anthony D Sandler
Journal:  J Pediatr Hematol Oncol       Date:  2006-07       Impact factor: 1.289

5.  Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival.

Authors:  S G DuBois; Y Kalika; J N Lukens; G M Brodeur; R C Seeger; J B Atkinson; G M Haase; C T Black; C Perez; H Shimada; R Gerbing; D O Stram; K K Matthay
Journal:  J Pediatr Hematol Oncol       Date:  1999 May-Jun       Impact factor: 1.289

Review 6.  DIMSCAN: a microcomputer fluorescence-based cytotoxicity assay for preclinical testing of combination chemotherapy.

Authors:  Nino Keshelava; Tomás Frgala; Jirí Krejsa; Ondrej Kalous; C Patrick Reynolds
Journal:  Methods Mol Med       Date:  2005

Review 7.  Targeting Stat3 in cancer therapy.

Authors:  Naijie Jing; David J Tweardy
Journal:  Anticancer Drugs       Date:  2005-07       Impact factor: 2.248

8.  Bone marrow mesenchymal stem cells provide an alternate pathway of osteoclast activation and bone destruction by cancer cells.

Authors:  Yasuyoshi Sohara; Hiroyuki Shimada; Cedric Minkin; Anat Erdreich-Epstein; Jan A Nolta; Yves A DeClerck
Journal:  Cancer Res       Date:  2005-02-15       Impact factor: 12.701

9.  Tyrosine hydroxylase indicates cell differentiation of catecholamine biosynthesis in neuroendocrine tumors.

Authors:  K Iwase; A Nagasaka; I Nagatsu; K Kiuchi; T Nagatsu; H Funahashi; T Tsujimura; A Inagaki; A Nakai; T Kishikawa
Journal:  J Endocrinol Invest       Date:  1994-04       Impact factor: 4.256

Review 10.  Interleukin-6: discovery of a pleiotropic cytokine.

Authors:  Tadamitsu Kishimoto
Journal:  Arthritis Res Ther       Date:  2006-07-28       Impact factor: 5.156

View more
  58 in total

1.  HCS campaign to identify selective inhibitors of IL-6-induced STAT3 pathway activation in head and neck cancer cell lines.

Authors:  Paul A Johnston; Malabika Sen; Yun Hua; Daniel P Camarco; Tong Ying Shun; John S Lazo; Gabriela Mustata Wilson; Lynn O Resnick; Matthew G LaPorte; Peter Wipf; Donna M Huryn; Jennifer R Grandis
Journal:  Assay Drug Dev Technol       Date:  2015-09       Impact factor: 1.738

2.  1,3,4-oxadiazole/chalcone hybrids: Design, synthesis, and inhibition of leukemia cell growth and EGFR, Src, IL-6 and STAT3 activities.

Authors:  Marwa Ali A Fathi; Amer Ali Abd El-Hafeez; Dalia Abdelhamid; Samar H Abbas; Monica M Montano; Mohamed Abdel-Aziz
Journal:  Bioorg Chem       Date:  2018-11-22       Impact factor: 5.275

3.  Sphingosine-1-Phosphate Receptor-1 Promotes Environment-Mediated and Acquired Chemoresistance.

Authors:  Veronica Lifshitz; Saul J Priceman; Wenzhao Li; Gregory Cherryholmes; Heehyoung Lee; Adar Makovski-Silverstein; Lucia Borriello; Yves A DeClerck; Hua Yu
Journal:  Mol Cancer Ther       Date:  2017-07-17       Impact factor: 6.261

4.  G-CSF Promotes Neuroblastoma Tumorigenicity and Metastasis via STAT3-Dependent Cancer Stem Cell Activation.

Authors:  Saurabh Agarwal; Anna Lakoma; Zaowen Chen; John Hicks; Leonid S Metelitsa; Eugene S Kim; Jason M Shohet
Journal:  Cancer Res       Date:  2015-04-23       Impact factor: 12.701

5.  Exosome-mediated transfer of microRNAs within the tumor microenvironment and neuroblastoma resistance to chemotherapy.

Authors:  Kishore B Challagundla; Petra M Wise; Paolo Neviani; Haritha Chava; Mariam Murtadha; Tong Xu; Rebekah Kennedy; Cristina Ivan; Xinna Zhang; Ivan Vannini; Francesca Fanini; Dino Amadori; George A Calin; Michael Hadjidaniel; Hiroyuki Shimada; Ambrose Jong; Robert C Seeger; Shahab Asgharzadeh; Amir Goldkorn; Muller Fabbri
Journal:  J Natl Cancer Inst       Date:  2015-05-13       Impact factor: 13.506

6.  Bone marrow-derived mesenchymal stromal cells promote survival and drug resistance in tumor cells.

Authors:  Scott A Bergfeld; Laurence Blavier; Yves A DeClerck
Journal:  Mol Cancer Ther       Date:  2014-02-06       Impact factor: 6.261

7.  Inhibition of STAT3 with the Generation 2.5 Antisense Oligonucleotide, AZD9150, Decreases Neuroblastoma Tumorigenicity and Increases Chemosensitivity.

Authors:  Seiichi Odate; Veronica Veschi; Shuang Yan; Norris Lam; Richard Woessner; Carol J Thiele
Journal:  Clin Cancer Res       Date:  2016-10-19       Impact factor: 12.531

8.  Macrophages potentiate STAT3 signaling in skeletal muscles and regulate pancreatic cancer cachexia.

Authors:  Surendra K Shukla; Spas D Markov; Kuldeep S Attri; Enza Vernucci; Ryan J King; Aneesha Dasgupta; Paul M Grandgenett; Michael A Hollingsworth; Pankaj K Singh; Fang Yu; Kamiya Mehla
Journal:  Cancer Lett       Date:  2020-04-25       Impact factor: 8.679

9.  Targeting PYK2 mediates microenvironment-specific cell death in multiple myeloma.

Authors:  M B Meads; B Fang; L Mathews; J Gemmer; L Nong; I Rosado-Lopez; T Nguyen; J E Ring; W Matsui; A R MacLeod; J A Pachter; L A Hazlehurst; J M Koomen; K H Shain
Journal:  Oncogene       Date:  2015-09-21       Impact factor: 9.867

Review 10.  More than the genes, the tumor microenvironment in neuroblastoma.

Authors:  Lucia Borriello; Robert C Seeger; Shahab Asgharzadeh; Yves A DeClerck
Journal:  Cancer Lett       Date:  2015-11-17       Impact factor: 8.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.